Integrated operations from raw-material procurement through manufacturing and packaging
First written in FY2018. 12 of 13 entries say "Restated". Latest entry: FY2026.
3 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「To meet customer requirements more fully, we also manufacture and sell finished formulations and conduct broad-based transactions with pharmaceutical manufacturers in Japan and overseas under a structure capable of integrated production from APIs through finished formulations.」
The group has reaffirmed its integrated in-house structure, combining the purchase and sale of active pharmaceutical ingredients with the manufacture and sale of finished formulations. - FY2025RestatedAnnual report
「To meet customer requirements more fully, we also manufacture and sell finished formulations and conduct broad-based transactions with pharmaceutical manufacturers in Japan and overseas under a structure capable of integrated production from APIs through finished formulations.」
The integrated structure combining API procurement and sales with the manufacture and sale of finished formulations has been reaffirmed. - FY2022-Q2RestatedAnnual report
「Under a business model that combines an importing business specializing in generic APIs with manufacturing and marketing capabilities for prescription pharmaceuticals, primarily injectables, we steadily supply high-quality, low-cost APIs to the Japanese market while meeting diverse needs in the pharmaceutical industry through the manufacture and sale of internally developed products and contract manufacturing for major pharmaceutical manufacturers.」
The group has reaffirmed an integrated model combining API imports, manufacturing and marketing centered on injectables, internally developed products and contract manufacturing. - FY2022-Q1RestatedAnnual report
「Against this backdrop, based on our business philosophy, “New Business Model Innovation,” our group operates a business model combining an import trading company for generic-drug APIs with manufacturing and marketing functions for prescription pharmaceuticals, primarily injectables. We stably supply high-quality, low-cost APIs to the Japanese market while meeting diverse needs in the pharmaceutical industry through the manufacture and sale of internally developed products and contract manufacturing for major pharmaceutical companies.」
The group has reaffirmed a business model that combines an API importing business with pharmaceutical manufacturing and marketing capabilities, including the manufacture and sale of internally developed products and contract manufacturing. - FY2021RestatedAnnual report
「Leveraging the strengths of having both an API trading company and finished-formulation and packaging companies within the group, we aim to generate synergies through consistently conducting procurement of raw materials, manufacturing and packaging within the group, thereby increasing profits, creating value and improving efficiency in each business division.」
The group continues to regard its integrated structure from API procurement through manufacturing and packaging as a business strength. - FY2021-Q2RestatedAnnual report
「Under a business model that combines an importing business specializing in generic APIs with manufacturing and marketing capabilities for prescription pharmaceuticals, primarily injectables」
The group has reaffirmed its integrated business model combining an API importing business with manufacturing and marketing capabilities for prescription pharmaceuticals, primarily injectables. - FY2021-Q1RestatedAnnual report
「Against this backdrop, based on our business philosophy, “New Business Model Innovation,” our group operates a business model combining an import trading company for generic-drug APIs with manufacturing and marketing functions for prescription pharmaceuticals, primarily injectables. We stably supply high-quality, low-cost APIs to the Japanese market while meeting diverse needs in the pharmaceutical industry through the manufacture and sale of internally developed products and contract manufacturing for major pharmaceutical companies.」
The group has reaffirmed its business model combining an API importing business with manufacturing and marketing capabilities for prescription pharmaceuticals, primarily injectables. - FY2020-Q2RestatedAnnual report
「With an integrated manufacturing structure covering everything from API procurement to finished products, we conduct broad-ranging transactions with pharmaceutical manufacturers in Japan and overseas.」
The integrated structure from API procurement through finished-product development, manufacturing and sales has been reaffirmed. - FY2020-Q1RestatedAnnual report
「With an integrated manufacturing structure covering everything from API procurement to finished products, we conduct broad-ranging transactions with pharmaceutical manufacturers in Japan and overseas.」
The integrated structure from API sales through finished-product development, manufacturing and sales has been reaffirmed. - FY2019RestatedAnnual report
「By handling everything from raw-material procurement through manufacturing and packaging within the Group, we aim to create synergies by increasing profits and generating added value in each business division and improving efficiency.」
The Group has reaffirmed its integrated structure, leveraging its API trading company, finished-product manufacturer and packaging company. - FY2019-Q3RestatedAnnual report
「Against this backdrop, our group imports and sells APIs, the raw materials for pharmaceuticals, with a focus on providing high-quality, low-cost imported APIs. We also develop, manufacture and sell finished pharmaceutical products, primarily injectables, and conduct broad-based transactions with pharmaceutical manufacturers in Japan and overseas under a structure that enables integrated manufacturing from API procurement through finished products.」
The integrated structure from API procurement through finished-product development, manufacturing and sales continues to form the foundation of the business. - FY2019-Q2RestatedAnnual report
「Against this backdrop, our group imports and sells APIs, the raw materials for pharmaceuticals, with a focus on providing high-quality, low-cost imported APIs. We also develop, manufacture and sell finished pharmaceutical products, primarily injectables, and conduct broad-based transactions with pharmaceutical manufacturers in Japan and overseas under a structure that enables integrated manufacturing from API procurement through finished products.」
The integrated structure from API import and sales through finished-product development, manufacturing and sales has been reaffirmed as the basis for business operations. - FY2018First statedAnnual report
「By handling everything from raw-material procurement through manufacturing and packaging within the Group, we aim to create synergies by increasing profits and generating added value in each business division and improving efficiency.」
A measure that leverages the Group’s ownership of an API trading company, a finished-product manufacturer and a packaging company.